文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

印度5岁以下儿童侵袭性肺炎链球菌病监测研究

Invasive pneumococcal disease in children aged younger than 5 years in India: a surveillance study.
PubMed 文献 · Lancet Infect Dis · 2016-12-10

该研究在印度11个邦的18家医院和10个哨点实验室对5岁以下儿童进行前瞻性和回顾性监测。2011至2015年共入组4377例患者,361例(8%)培养确诊,其中肺炎占58%、脑膜炎占35%;总体病死率3%,侵袭性肺炎链球菌病患者病死率8%。常见血清型为14、1、5和19F,青霉素不敏感率8%,多重耐药率9%。

要点

  • 印度5岁以下儿童侵袭性肺炎链球菌病以肺炎和脑膜炎为主,血清型14、1、5、19F最常见。
  • 培养确诊患者中青霉素不敏感率8%,复方磺胺甲噁唑耐药率66%,多重耐药率9%。
  • 侵袭性肺炎链球菌病患者病死率达8%,需持续监测以支持疫苗引入决策。

核心结论

  • 印度5岁以下儿童侵袭性肺炎链球菌病疾病负担较重,血清型分布和耐药模式需持续监测以指导疫苗引入决策。

研究设计与样本

  • 前瞻性医院为基础和回顾性实验室为基础的监测研究,覆盖印度11个邦的18家医院或机构中心及10个哨点实验室。

主要发现

  • 2011年1月1日至2015年6月30日共入组4377例患者,361例(8%)为培养确诊肺炎链球菌病。
  • 226例有完整临床数据的患者中,132例(58%)表现为肺炎,78例(35%)表现为脑膜炎,16例(7%)为其他临床状况。
  • 总体131例(3%)死亡,侵袭性肺炎链球菌病患者中29例(8%)死亡。
  • 血清型14占52/361(14%)、1占49/361(14%)、5占37/361(10%)、19F占33/361(9%)。
  • 青霉素不敏感29/361(8%),复方磺胺甲噁唑耐药239/361(66%),红霉素耐药132/361(37%),氯霉素耐药33/361(9%),多重耐药33/361(9%)。

临床怎么用

  • 监测数据可帮助了解印度5岁以下儿童侵袭性肺炎链球菌病的血清型分布和耐药格局。
  • 研究结果可为印度引入蛋白结合疫苗的决策提供参考依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive pneumococcal disease continues to be a major cause of morbidity and mortality among children younger than 5 years of age in India. We aimed to provide nationally representative data for the pattern of disease due to Streptococcus pneumoniae, trends in the serotype of invasive pneumococci, and invasive pneumococci antimicrobial resistance patterns, in India. METHODS: In this prospective hospital-based and retrospective laboratory-based surveillance study, we prospectively enrolled children aged younger than 5 years with suspected or proven invasive pneumococcal disease from 18 hospitals or institutional centres and retrospectively included laboratory-confirmed pneumococcal isolates from ten sentinel laboratories, together representing 11 states in India. Eligibility criteria were fever higher than 38°C without localising symptoms, clinical presentation of suspected meningitis or pneumonia, and evidence of radiographic pneumonia. We cultured blood and other normally sterile body fluids, reconfirmed and serotyped pneumococcal isolates, and established antimicrobial susceptibility using standard study protocols. FINDINGS: Between Jan 1, 2011, and June 30, 2015, we enrolled 4377 patients. Among 361 (8%) patients with culture-proven pneumococcal disease, all clinical data were known for 226 (63%); among these patients, 132 (58%) presented with pneumonia, 78 (35%) presented with meningitis, and 16 (7%) had other clinical conditions. 131 (3%) died overall and 29 (8%) patients with invasive pneumococcal disease died. Serotypes 14 (52 [14%] of 361), 1 (49 [14%]), 5 (37 [10%]), and 19F (33 [9%]) were the most common. Penicillin non-susceptibility occurred in isolates from 29 (8%) patients, co-trimoxazole resistance occurred in 239 (66%), erythromycin resistance occurred in 132 (37%), and chloramphenicol resistance occurred in 33 (9%). We found multidrug resistance in 33 (9%) of 361 patients. INTERPRETATION: The proportion of positive blood cultures, number of isolates, geographical representation, and data generated over the 4·5 years of the study are representative of data for most of India. Continued surveillance is warranted as the decision to introduce protein conjugated vaccine in India is made. FUNDING: GlaxoSmithKline India.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Manoharan A, Manchanda V, Balasubramanian S, et al. Invasive pneumococcal disease in children aged younger than 5 years in India: a surveillance study. Lancet Infect Dis. 2016. PMID: 27956163. doi:10.1016/S1473-3099(16)30466-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。